Unichem Laboratories Ltd Stock Price Today (NSE: UNICHEMLAB)
Fundamental Score
Unichem Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Unichem Laboratories Ltd share price today is ₹374.65, up +0.00% on NSE/BSE as of 17 February 2026. Unichem Laboratories Ltd (UNICHEMLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.21K (Cr). The 52-week high for UNICHEMLAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 22.07x, UNICHEMLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 5.59% and a debt-to-equity ratio of 0.21.
Unichem Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Unichem Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Unichem Laboratories Share Price: A Financial Stability Analysis
The pharmaceutical industry is currently experiencing a period of consolidation, driven by patent expirations and increasing R&D costs, making careful financial analysis crucial for investors. This report examines the financial stability of Unichem Laboratories based on publicly available data. The current Unichem Laboratories share price stands at ₹396.3500061035156. This analysis forms part of a larger 80-parameter fundamental audit, verified by Sweta Mishra, and uses observational language to assess the company's financial health.
A key metric is the Price-to-Earnings (PE) ratio. Unichem Laboratories' PE of 22.07 suggests that investors are willing to pay ₹22.07 for every rupee of earnings. When compared to its sector peers, it's important to consider the relative value. For example, we can contrast Unichem Laboratories Ltd with peers like
Mankind Pharma Ltd. While a deep dive into Mankind Pharma Ltd is outside the scope of this specific analysis, differences in PE ratios can often be attributed to variations in perceived management quality, growth prospects, and risk profiles. A lower PE ratio relative to peers might indicate undervaluation, but could also reflect concerns about the company's future performance or inherent risks.Return on Capital Employed (ROCE) is another critical indicator of financial stability. Unichem Laboratories reports a ROCE of 6.24%. This percentage represents the return a company is generating from its capital employed. A lower ROCE suggests that the company is not efficiently utilizing its capital to generate profits. The 6.24% ROCE, viewed in the context of the pharmaceutical industry, raises questions about the company's competitive advantage or "moat." A higher ROCE typically indicates a stronger ability to protect market share and generate sustained profits. The impact of this ROCE on Unichem's long-term financial stability warrants further investigation. A low ROCE can erode the company's ability to reinvest in growth opportunities and maintain its market position.
This analysis is based on publicly available information and uses observational language. This should not be construed as investment advice. A thorough review of the company's financial statements, industry trends, and competitive landscape is necessary before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Unichem Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of UNICHEMLAB across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Attractive Valuation (P/E: 22.07 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (83.92%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (13.85% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (29.11% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (29.11% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.21)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.86x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (70.22%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (5.59%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.24%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Negative Free Cash Flow (₹-905.71 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Unichem Laboratories Ltd Financial Statements
Comprehensive financial data for Unichem Laboratories Ltd including income statement, balance sheet and cash flow
About UNICHEMLAB (Unichem Laboratories Ltd)
Unichem Laboratories Ltd (UNICHEMLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹3.21K (Cr). Unichem Laboratories Ltd has delivered a Return on Equity (ROE) of 5.59% and a ROCE of 6.24%. The debt-to-equity ratio stands at 0.21, reflecting the company's capital structure. Investors tracking UNICHEMLAB share price can monitor key metrics including P/E ratio, promoter holding of 70.22%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
UNICHEMLAB Share Price: Frequently Asked Questions
What is the current share price of Unichem Laboratories Ltd (UNICHEMLAB)?
As of 17 Feb 2026, 10:25 am IST, Unichem Laboratories Ltd share price is ₹374.65. The UNICHEMLAB stock has a market capitalisation of ₹3.21K (Cr) on NSE/BSE.
Is UNICHEMLAB share price Overvalued or Undervalued?
UNICHEMLAB share price is currently trading at a P/E ratio of 22.07x, compared to the industry average of 31.77x. Based on this relative valuation, the Unichem Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of UNICHEMLAB share price?
The 52-week high of UNICHEMLAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Unichem Laboratories Ltd share price?
Key factors influencing UNICHEMLAB share price include quarterly earnings growth (Sales Growth: 14.11%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Unichem Laboratories Ltd a good stock for long-term investment?
Unichem Laboratories Ltd shows a 5-year Profit Growth of 29.11% and an ROE of 5.59%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.21 before investing in UNICHEMLAB shares.
How does Unichem Laboratories Ltd compare with its industry peers?
Unichem Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare UNICHEMLAB share price P/E of 22.07x and ROE of 5.59% against the industry averages to determine competitive standing.
What is the P/E ratio of UNICHEMLAB and what does it mean?
UNICHEMLAB share price has a P/E ratio of 22.07x compared to the industry average of 31.77x. Investors pay ₹22 for every ₹1 of annual earnings.
How is UNICHEMLAB performing according to Bull Run's analysis?
UNICHEMLAB has a Bull Run fundamental score of 56.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does UNICHEMLAB belong to?
UNICHEMLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Unichem Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for UNICHEMLAB?
UNICHEMLAB has an ROE of 5.59%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Unichem Laboratories Ltd generates profits from shareholders capital.
How is UNICHEMLAB debt-to-equity ratio and what does it indicate?
UNICHEMLAB has a debt-to-equity ratio of 0.21, which indicates conservative financing with low financial risk.
What is UNICHEMLAB dividend yield and is it a good dividend stock?
UNICHEMLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Unichem Laboratories Ltd shares.
How has UNICHEMLAB share price grown over the past 5 years?
UNICHEMLAB has achieved 5-year growth rates of: Sales Growth 13.85%, Profit Growth 29.11%, and EPS Growth 29.11%.
What is the promoter holding in UNICHEMLAB and why does it matter?
Promoters hold 70.22% of UNICHEMLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Unichem Laboratories Ltd.
What is UNICHEMLAB market capitalisation category?
UNICHEMLAB has a market capitalisation of ₹3215 crores, placing it in the Small-cap category.
How volatile is UNICHEMLAB stock?
UNICHEMLAB has a beta of N/A. A beta > 1 suggests the Unichem Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is UNICHEMLAB operating profit margin trend?
UNICHEMLAB has a 5-year average Operating Profit Margin (OPM) of 6.06%, indicating the company's operational efficiency.
How is UNICHEMLAB quarterly performance?
Recent quarterly performance shows Unichem Laboratories Ltd YoY Sales Growth of 14.11% and YoY Profit Growth of 83.92%.
What is the institutional holding pattern in UNICHEMLAB?
UNICHEMLAB has FII holding of 0.99% and DII holding of 10.74%. Significant institutional holding often suggests professional confidence in the Unichem Laboratories Ltd stock.